Global Point of Care Infectious Disease Market – Industry Trends and Forecast to 2031

Point of Care Infectious Disease Market Analysis and Size

Point of care infectious disease market offers rapid diagnostic tests for various diseases such as HIV, malaria, and influenza. Its applications include timely diagnosis in remote areas, emergency departments, and during outbreaks. These tests enable quick decision-making, efficient patient management, and contribute to the containment of infectious diseases.                                

Data Bridge Market Research analyses that the global point of care infectious disease market, which was USD 16.95 billion in 2023, is expected to reach USD 29.56 billion by 2031, and is expected to undergo a CAGR of 7.2% during the forecast period of 2024 to 2031. This indicates that the market value. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Report Scope and Market Segmentation

Market Definition

Point-of-care infectious disease refers to diagnostic tests conducted at or near the patient, providing rapid results for immediate treatment decisions. These tests are often performed outside traditional laboratory settings, enabling timely identification of infectious agents such as bacteria or viruses, crucial for effective disease management and control.            

Global Point of Care Infectious Disease Market Dynamics

Drivers

• Growing Prevalence of Infectious Diseases

The rising global incidence of infectious diseases fuels the demand for point-of-care diagnostics, crucial for immediate outbreak management. These tests offer rapid identification of pathogens, enabling timely interventions to contain outbreaks, reduce transmission, and improve public health responses in the face of emerging infectious threats.

• Government Initiatives for Accessible Treatment

Government Initiatives play a pivotal role in driving the adoption of point-of-care diagnostics for infectious diseases. Supportive policies and funding allocations facilitate research, development, and deployment of innovative tools. Collaboration with healthcare organizations ensures accessibility and affordability, driving market growth while addressing public health challenges effectively.

Opportunities

• Shift towards Personalized Medicine Creates Demand

Point-of-care diagnostics are pivotal in the rising trend of personalized medicine, tailoring treatments to individuals based on genetic makeup, lifestyle, and other factors. These diagnostics offer real-time patient data, enabling precise treatment decisions. This shift revolutionizes healthcare, emphasizing targeted therapies for improved outcomes and patient-centric care.

• Advancements in Technology for Efficient Disease Detection

Advancements in technology, including miniaturization and enhanced sensitivity of diagnostic devices, play a pivotal role in driving the growth of the point-of-care infectious disease market. These innovations enable the development of more portable, user-friendly, and accurate diagnostic tools, facilitating rapid and efficient disease detection at the patient's bedside expanding access to timely healthcare interventions. 

Restraints/Challenges

• Growing Data Security and Privacy Concern

Ensuring robust data security and patient privacy in point-of-care infectious disease testing challenges the market by necessitating costly compliance measures with regulations such as HIPAA. Failure to meet these standards result into legal consequences, erode consumer trust, and hinder market adoption of these vital healthcare technologies. 

• Limited Storage and Shelf Life Leads to Product Wastage

Storage and shelf life issues are significant hurdles for the point-of-care infectious disease market. They elevate the risk of product wastage, logistical complications, and compromised test accuracy, especially in resource-limited or remote settings where maintaining consistent storage conditions can be challenging, impeding effective deployment and usability of diagnostics. 

This global point of care infectious disease market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global point of care infectious disease market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Developments

• In January 2023, Cipla Inc. launched "Cippoint," a point-of-care testing device, revolutionizing the infectious disease market by enhancing rapid diagnostics accessibility. This strategic move reinforces Cipla's commitment to healthcare challenges, solidifying their market position and meeting the escalating demand for convenient testing solutions
• In March 2020, LumiraDx Limited's collaboration with Chembio Diagnostics to develop a COVID-19 point-of-care test, strategically entering the infectious disease market. This joint endeavor positions LumiraDx to meet the urgent need for accessible diagnostic solutions during the global pandemic, capturing a new market segment
• In February 2020, Abbott launches a rapid molecular point-of-care test for COVID-19, providing results in five minutes, marked a breakthrough in infectious disease diagnostics. Operating on the ID NOW platform, this innovation addressed the critical demand for swift and accessible testing during the pandemic, enhancing Abbott's industry position
• In February 2020, Nanopin and ThermoFisher formed a strategic partnership to advance infectious disease detection technologies. This collaboration provides ThermoFisher with a new platform for expansion in the point-of-care infectious disease market, leveraging Nanopin's expertise to bolster its presence in this rapidly growing sector

Global Point of Care Infectious Disease Market Scope

The global point of care infectious disease market is segmented on the basis of technological offering, clinical application, disease, and end users. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Technological Offering

• Molecular Diagnostic
• Solid Phase
• Lateral Flow
• Agglutination Assays
• Flow-Through

 Clinical Application

• Tropical Diseases
• Inflammatory Diseases
• Liver Disorders
• HIV
• Respiratory Disorders
• HAIs
• Sexually Transmitted Diseases
• Others

 Disease

• Hepatitis B Virus
• Pneumonia/ Streptococcus Associated Infections
• Influenza
• Clostridium Difficile Infections
• Hepatitis C Virus
• CDI
• MRSA
• TB

 End Users

• Hospitals
• Nursing Home
• Home-Care
• Clinics
• Diagnostic and Research Laboratories
• Others

Global Point of Care Infectious Disease Market Regional Analysis/Insights

The global point of care infectious disease market is analysed and market size insights and trends are provided by country, technological offering, clinical application, disease, and end users as referenced above.

The countries covered in the global point of care infectious disease market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the point of care infectious disease market, driven by increasing adoption of point of care technology and rising approvals for infectious disease products. This region's prominence is expected to persist throughout the forecast period, fueling market growth.

Asia-Pacific region will witness the highest growth rate during the forecast period of 2024 to 2031. This surge is attributed to the rapid increase in the geriatric population, rising cases of infectious diseases, and substantial investments in healthcare infrastructure enhancement.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Healthcare Infrastructure growth Installed base and New Technology Penetration

The global point of care infectious disease market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for global point of care infectious disease market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the global point of care infectious disease market. The data is available for historic period 2016-2021.

Competitive Landscape and Global Point of Care Infectious Disease Market Share Analysis

The global point of care infectious disease market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global point of care infectious disease market.

Some of the major players operating in the global point of care infectious disease market are:

• Abbott (U.S.)
• Abaxis (U.S.)
• PTS Diagnostics (U.S.)
• F. Hoffmann-La Roche Ltd (Switzerland)
• Samsung Medison Co., Ltd. (South Korea)
• Bio-Rad Laboratories, Inc. (U.S.)
• The Menarini Group (Italy)
• Nova Biomedical (U.S.)
• AccuBioTech Co., Ltd. (China)
• BD (U.S.)
• Chembio Diagnostics, Inc. (U.S.)
• Danaher Corporation  (U.S.)
• EKF DIAGNOSTICS HOLDINGS PLC (U.K.)
• Johnson & Johnson Services, Inc. (U.S.)
• QuidelOrtho Corporation. (U.S.)
• Siemens (Germany)
• Trinity Biotech Ireland (Ireland)
• MedMira Inc (Canada)

SKU-33677